11446 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

services are evaluated through their 

multiple features or ‘attributes,’ and that 

an individual’s choice of a product or 

service is a function of the utility of 

each attribute option or ‘level.’ 

Attributes and their corresponding 

levels are chosen to represent the 

features of medications, devices, and 

healthcare services that are relevant to 

a healthcare decision. 

The proposed information collection 

will include two separate DCE surveys: 

One for priority populations and one for 

clinicians. The survey uses an 

experimental design to combine levels 

from each attribute into hypothetical 

product profiles and to pair profiles into 

choice tasks. The experimental design 

will be split into several blocks or 

versions. Each equally sized block will 

have 8–12 questions, and questions will 

not be repeated across blocks. 

Participants will be randomly assigned 

to a block and will see only one block 

when completing the survey instrument. 

The study’s target population 

includes persons ages 18 and older who 

either (1) prescribe PrEP or (2) are in the 

following priority population groups 

selected because they have the highest 

rates of HIV acquisition and are in need 

for HIV prevention services: 

• Gay, bisexual, and other men who 

have sex with men subdivided by race/ 

ethnicity: 

Æ Black/African American, 

Æ Hispanic/Latino, or 

Æ White; 

• Black/African American 

heterosexual persons subdivided by 

biological sex: 

Æ Men or 

Æ Women; 

• Transgender women; and 

• Persons who inject drugs. 

To be eligible for the study, potential 

participants in each of the priority 

population groups must be 18 years of 

age or older, living without HIV, and 

meet the U.S. Public Health Service 

(USPHS) indications for offering PrEP as 

described in the 2021 USPHS Clinical 

Practice Guidelines. 

The study sample will be recruited 

from cities with high numbers of annual 

HIV diagnoses within the 57 priority 

jurisdictions identified as part of the 

EHE initiative. Participants will be 

randomly assigned to a block when they 

are sent their unique DCE survey link 

and will only complete the set of choice 

tasks in that block. Throughout the 

study, we will closely monitor 

recruitment and data collection to 

ensure that screening criteria are being 

met, key demographic groups are 

adequately represented, and survey 

completion rates are acceptable. 

Participation is voluntary. For this 

study, CDC intends to screen 

approximately 9,200 participants and 

enroll 1,840 participants. CDC estimates 

that approximately 15 percent of 

enrolled participants will be removed 

from the analysis due to fraud or 

incomplete data, resulting in a final 

analysis sample size of 1,600 

participants. At 25 minutes per survey 

and 10 minutes per combined screening 

and consent, CDC requests approval for 

an estimated 2,341 annualized burden 

hours. There are no costs to respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

(Type of) respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Black/African American, Hispanic/ 

Latino, or White men who are gay, 

bisexual or have sex with men, 

ages 18+ in the United States.

Screening & Consent .......................

Survey ..............................................

3,450 

690 

1 

1 

10/60 

25/60 

587 

290 

Black/African American Heterosexual 

Cisgender Men or Women, ages 

18+, in the United States.

Screening & Consent .......................

Survey ..............................................

2,300 

460 

1 

1 

10/60 

25/60 

391 

194 

Transgender Women, ages 18+, in 

the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Persons who inject drugs, ages 18+, 

in the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Clinical providers who prescribe 

PrEP, in the United States.

Screening & Consent .......................

Survey ..............................................

1,150 

230 

1 

1 

10/60 

25/60 

196 

97 

Total ........................................... ........................................................... ........................ ........................ ........................ 2,341 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04190 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–1286; Docket No. CDC–2022– 

0029] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled, Annual Reporting of the Rape 

Prevention and Education (RPE) 

Program. The RPE Program is the 

principal federally funded program 

focused on sexual violence (SV) 

prevention. This data collection allows 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11447 

CDC to collect information about the 

implementation and outcomes of CE19– 

1902 cooperative agreement. 

DATES: CDC must receive written 

comments on or before May 2, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0029 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Annual Reporting of the Rape 

Prevention and Education (RPE) 

Program (OMB Control No. 0920–1286, 

Exp. 3/31/2023)—Revision—National 

Center for Injury Prevention and Control 

(NCIPC), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

This is a request for a Revision of the 

currently approved Annual Reporting of 

the Rape prevention and Education 

(RPE) Program collection (OMB Control 

No. 0920–1286, Exp. 03/31/2023). This 

Revision is being requested to continue 

to collect information related to 

implementation and outcomes annually 

from 53 recipients or their designated 

delegates funded through the funding 

opportunity, CE19–1902. Sexual 

violence (SV) is a major public health 

problem. One in three women and one 

in four men experienced SV involving 

physical contact during their lifetimes. 

Nearly one in five women and one in 38 

men have experienced completed or 

attempted rape. SV starts early: One in 

three female and one in four male rape 

victims experienced it for the first time 

between 11–17 years old. CDC’s 

Division of Violence Prevention (DVP) 

provides national leadership in 

prevention of SV perpetration and 

victimization before it begins (i.e., 

primary prevention). DVP administers 

the RPE Program, which provides 

funding to health departments in all 50 

states, the District of Columbia (DC), 

Puerto Rico, Guam, the U.S. Virgin 

Islands, and the Commonwealth of 

Northern Mariana Islands. 

The RPE Program is the principal 

federally funded program focused on SV 

primary prevention. Collecting 

information about the implementation 

and outcomes of CE19–1902 cooperative 

agreement through the online data 

system (DVP Partners Portal) is crucial 

to informing SV prevention nationally; 

enhancing accountability of the use of 

federal funds; providing timely program 

reports and responses to information 

requests, such as Congressional requests 

mandated by the authorizing legislation; 

improving real-time communications 

between CDC and RPE recipients; and 

strengthening CDC’s capacity to provide 

responsive data-driven technical 

assistance and to monitor and evaluate 

recipients’ progress and performance. 

Information will be collected annually 

from recipients through the DVP 

Partners Portal. The DVP Partners Portal 

is organized by forms, which are further 

organized by sections and sub-sections. 

Recipients and program staff are able to 

review information reported in previous 

years within the DVP Partners Portal per 

their authenticated access. In addition, 

information from previous reports will 

be carried over and pre-populated for 

the next annual reporting as 

appropriate. Thus, with DVP Partners 

Portal most of the burden is required 

during the initial population of 

information (Year 1), Recipients will 

only need to enter changes, provide 

progress information, and add new 

information after Year 1. 

CDC will use the information to be 

collected for the following: 

• Enhance accountability of the use of 

federal funds 

• Provide timely program reports and 

responses to information request 

• Improve real-time communications 

between CDC and recipients 

• Strengthen CDC’s capacity to provide 

responsive and data-driven TA 

• Strengthen CDC’s capacity to monitor 

and evaluate recipients’ progress and 

performance towards activities 

required as part of the cooperative 

agreement 

• Allow both CDC and recipients to 

track their own state activities and 

outcomes, and ensure alignment 

between their state and local activities 

• Generate a variety of routine and 

customizable reports specifically for 

each recipient and in aggregate 

nationally for CDC stakeholders 

The total estimated annual burden for 

this collection is 424 hours. CDC is 

requesting a one-year approval. There is 

no cost to respondents other than their 

time. 


jspears on DSK121TN23PROD with NOTICES1
11448 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

(in hours) 

RPE-funded Health Departments (State, DC, and 

Territories) and their Designated Delegates.

Annual Reporting—Initial Population ......................

Annual Reporting—Subsequent Reporting .............

53 

53 

1 

2 

4 

2 

212 

212 

Total ................................................................. ................................................................................. .................... ........................ .................... 424 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–04192 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—RFA–CK–22– 

006, Clinical and Applied Research 

Strategies for the Prevention and 

Control of Fungal Diseases; 

Cancellation of Meeting 

AGENCY: Centers for Disease Control and 

Prevention, Department of Health and 

Human Services. 

ACTION: Notice. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given of a change in the meeting 

of the Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—RFA–CK–22– 

006, Clinical and Applied Research 

Strategies for the Prevention and 

Control of Fungal Diseases; April 14, 

2022, 10:00 a.m.–5:00 p.m., EDT. The 

teleconference was published in the 

Federal Register on February 14, 2022, 

Volume 87, Number 30, page 8251. 

This meeting is being canceled in its 

entirety. 

FOR FURTHER INFORMATION CONTACT: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, CDC, National 

Center for HIV, Viral Hepatitis, STD, 

and TB Prevention, 1600 Clifton Road 

NE, Mailstop US8–1, Atlanta, Georgia 

30329, (404) 718–8833, ganderson@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04259 Filed 2–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3427–N] 

Medicare Program; Request for 

Nominations for Members for the 

Medicare Evidence Development & 

Coverage Advisory Committee 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

request for nominations for membership 

on the Medicare Evidence Development 

& Coverage Advisory Committee 

(MEDCAC). Among other duties, the 

MEDCAC provides advice and guidance 

to the Secretary of the Department of 

Health and Human Services (the 

Secretary) and the Administrator of the 

Centers for Medicare & Medicaid 

Services (CMS) concerning the 

adequacy of scientific evidence 

available to CMS in making coverage 

determinations under the Medicare 

program. The MEDCAC’s fundamental 

purpose is to support the principles of 

an evidence-based determination 

process for Medicare’s coverage 

policies. MEDCAC panels provide 

advice to CMS on the strength of the 

evidence available for specific medical 

treatments and technologies through a 

public, participatory, and accountable 

process. 

DATES: Nominations must be received 

by Monday, March 28, 2022. 

ADDRESSES: You may mail nominations 

for membership to the following 

address: Centers for Medicare & 

Medicaid Services, Center for Clinical 

Standards and Quality, Attention: Ruth 

McKesson, 7500 Security Boulevard, 

Mail Stop: S3–02–01, Baltimore, MD 

21244 or send via email to 

MEDCACnomination@cms.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Ruth McKesson, MEDCAC Coordinator, 

Centers for Medicare & Medicaid 

Services, Center for Clinical Standards 

and Quality, Coverage and Analysis 

Group, S3–02–01, 7500 Security 

Boulevard, Baltimore, MD 21244 or 

contact Ms. McKesson by phone (410) 

786–8611 or via email at 

Ruth.McKesson@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Secretary signed the initial 

charter for the Medicare Coverage 

Advisory Committee (MCAC) on 

November 24, 1998. A notice in the 

Federal Register (63 FR 68780) 

announcing establishment of the MCAC 

was published on December 14, 1998. 

The MCAC name was updated to more 

accurately reflect the purpose of the 

committee and on January 26, 2007, the 

Secretary published a notice in the 

Federal Register (72 FR 3853), 

announcing that the Committee’s name 

changed to the Medicare Evidence 

Development & Coverage Advisory 

Committee (MEDCAC). The current 

Secretary’s Charter for the MEDCAC is 

available on the CMS website at: https:// 

www.cms.gov/Regulations-andGuidance/Guidance/FACA/Downloads/ 

medcaccharter.pdf or you may obtain a 

copy of the charter by submitting a 

request to the contact listed in the FOR

FURTHER INFORMATION section of this 

notice. 

The MEDCAC is governed by 

provisions of the Federal Advisory 

Committee Act, Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formulation and 

use of advisory committees, and is 

authorized by section 222 of the Public 

Health Service Act as amended (42 

U.S.C. 217A). 

We are requesting nominations for 

candidates to serve on the MEDCAC. 

Nominees are selected based upon their 

individual qualifications and not solely 

as representatives of professional 

associations or societies. We wish to 


jspears on DSK121TN23PROD with NOTICES1